MONTES ARCHIMEDES ACQUISITION CORP PC
MONTES ARCHIMEDES ACQUISITION CORP LICENSE

Roivant subsidiary Immunovant, for example, merged with SPAC Health Sciences Acquisition Corp. SPAC deals can offer private companies a way to go public with less concern about market volatility and allow earlier investors to keep a larger stake. Though SPACs have been around for years, they picked up considerable momentum in the tech and biotech industries last year. Going public is the next step, although the company chose to forgo the traditional IPO route in favor of merging with a SPAC, which are publicly traded investment vehicles formed to buy or combine with a target private company.

MONTES ARCHIMEDES ACQUISITION CORP LICENSE

The change coincided with Roivant's growing ambitions to advance discovery and early-stage programs as well as license its more advanced prospects. In January, Ramaswamy switched roles from CEO to executive chairman and promoted longtime chief financial officer Matthew Gline to the firm's top role.

Ownership in publicly traded subsidiaries Immunovant and Sio Gene Therapies (formerly Axovant) and biotech Arbutus Biopharma are worth about $1.1 billion combined, according to the filing. The Japanese drugmaker still has an option to buy six more.Īn investor presentation outlining the proposed SPAC merger showed Roivant made $1.9 billion on the $433 million it invested in the subsidiaries and technology sold to Sumitomo. Roivant offloaded five subsidiaries through a wide-ranging 2019 alliance with Sumitomo Dainippon Pharma. Two Roivant companies have produced marketed medicines and a third could follow next year. Several of its other companies, like Myovant, Dermavant and Immunovant, have gone public through IPOs and SPAC mergers. Axovant Sciences, the first Roivant company to go public, restructured and changed its name after a high-profile, unsuccessful plan to license and test a shelved Alzheimer's drug from GlaxoSmithKline.īut Roivant has continued to grow. That effort hasn't been without its failures. Since it started up in 2014, the company has brought over 40 medicines into clinical development. BridgeBio and PureTech are both publicly traded, and Centessa outlined plans for an initial public offering a few weeks ago. Roivant isn't alone in this approach a growing number of companies, such as BridgeBio, PureTech Health and most recently, Centessa Pharmaceuticals, have been built with similar 'hub-and-spoke' style strategies. Each are meant to advance drugs in specific therapeutic areas. Roivant, which Ramaswamy formed in 2014, is the parent company for a group of similarly named 'Vant' subsidiaries. We look forward to representing you in this case.The proposed merger marks the latest step in a seven-year effort by biotech investor Vivek Ramaswamy to build a life sciences company that plucks drugs from the shelves of pharmaceutical companies and houses them within smaller biotechs for development. During the course of this litigation, you authorize us to employ, share work and/or fees with other attorneys or law firms to prosecute your case. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. Should we obtain a favorable result, you authorize us to ask the court to award us compensation or seek reimbursement of expenses and up to one-third of any monetary class fund, or to negotiate and obtain a fee amount from defendants to be paid by the defendants, or its insurer or successor, but we will never ask you to pay any of the costs of this litigation.Īs the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees or costs.

We agree to advance all expenses in the litigation, which means that you are not liable or responsible to pay any of the expenses of the action, whether attorneys’ fees or costs. throughout the litigation and/or closing of the transaction.

prior to the recent takeover announcement and that you must maintain ownership in Montes Archimedes Acquisition Corp. As a named plaintiff, you acknowledge that you owned shares in Montes Archimedes Acquisition Corp. and/or its board of directors or officers.

MONTES ARCHIMEDES ACQUISITION CORP PC

This confirms that you have retained Monteverde & Associates PC to file an action with a complaint against Montes Archimedes Acquisition Corp. To start a Class Action lawsuit, please sign the Montes Archimedes Acquisition Corp.

Montes archimedes acquisition corp